Gilead Sciences, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Gilead Sciences has scheduled its 2025 Annual Meeting for May 7, 2025, and is soliciting shareholder votes on director elections, auditor ratification, executive compensation, and several stockholder proposals.
NASDAQ
Gilead Sciences is focusing on innovation in virology, oncology, and inflammation to drive long-term growth, highlighted by the potential FDA approval of lenacapavir, a twice-yearly injection for HIV prevention.
NASDAQ
DEFA14A: Gilead Sciences Sets Date for 2024 Annual Meeting, Outlines Key Proposals for Shareholder Vote
Gilead Sciences has scheduled its 2024 Annual Meeting for May 8, 2024, and is seeking shareholder votes on director elections, auditor ratification, executive compensation, and several other proposals.
NASDAQ
DEF 14A: Gilead Sciences Aims for 10+ Transformative Therapies by 2030, Highlights Growth in HIV and Oncology
Gilead Sciences outlines its strategic priorities, including bringing 10+ transformative therapies to patients by 2030 and maximizing near-term revenue growth, in its 2024 Proxy Statement.